A β-Glucuronidase-Responsive Albumin-Binding Prodrug of a Potent Focal Adhesion Kinase Inhibitor for Targeted Cancer...

Area of Science:

• Oncology
• Drug Delivery
• Biochemistry

Background:

• Focal adhesion kinase (FAK) is crucial in cancer development and malignancy.
• Current FAK inhibitors lack cancer cell selectivity and specificity, hindering clinical translation.
• Targeting FAK remains a key strategy for cancer therapy.

Purpose of the Study:

• To synthesize and evaluate a prodrug for selective FAK inhibitor delivery in solid tumors.
• To investigate the prodrug's activation mechanism and therapeutic efficacy.
• To assess the prodrug's impact on breast cancer cell cycle progression.

Main Methods:

• Synthesis of a trimeric β-glucuronidase-responsive albumin-binding prodrug.
• In vitro biological evaluation using MDA-MB-231 breast cancer cells.
• Mechanistic studies on cell cycle progression and FAK inhibition.

Main Results:

• The prodrug demonstrated potent inhibition of breast cancer cell growth (IC50 = 0.63 ± 0.02 μM) upon β-glucuronidase activation.
• Enzymatic activation led to cell cycle arrest in the G2/M phase.
• The albumin-binding moiety facilitated targeted delivery within solid tumors.

Conclusions:

• The developed prodrug enables selective FAK inhibitor delivery, overcoming limitations of current therapies.
• This β-glucuronidase-responsive system shows significant potential for FAK-targeted cancer treatment.
• The prodrug strategy warrants further investigation for solid tumor therapy.